IASLC 2024 World Conference on Lung Cancer
Find the latest updates on lung cancer treatment and research from the IASLC 2024 World Conference on Lung Cancer.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Rilvegostomig showed a favorable safety profile and encouraging preliminary efficacy in NSCLC.
The trial is investigating nogapendekin alfa inbakicept-pmln in combination with immune checkpoint inhibitor therapy.
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The three-year survival rate in the 2020 cohort of patients with NSCLC was more than double that of the 2000 cohort.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
The 5-year scoping review provided insights on the different abstracts and educational content presented at 12 meetings.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Gene Ho, MPH, discusses real-world data on adverse events and survival outcomes with immunotherapy for NSCLC.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Jill Feldman, a patient advocate, discusses how the lexicon can improve communication and empower patients.
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Robert E. Merritt, MD, MBA, FACS, discusses the analysis he presented at the IASLC 2024 World Conference on Lung Cancer.
The real-world study was presented at the IASLC 2024 World Conference on Lung Cancer.
Dr. Rolfo discusses results of an analysis that evaluated the impact of BMI on TTFields therapy.
Dr. Leighl explains PALOMA-3 data presented at the IASLC 2024 World Conference on Lung Cancer.
Researchers shared an updated safety analysis from the trial at the IASLC 2024 World Conference on Lung Cancer.
Ken Culver, MD, Director of Research and Clinical Affairs at ALK Positive, discusses the on-going ALK Life Study.
Dr. Halmos weighs in on HARMONi-2, TROPION-Lung 01, the SOHO-01 and Beamion LUNG-1 studies, and more.
The studies were highlighted as plenary presentations during a Presidential Symposium at WCLC 2024.
Rilertinib showed significantly longer progression-free survival compared with gefitinib.
Plinabulin combined with docetaxel showed improved survival in patients with wild-type EGFR NSCLC.
Eric Singhi, MD, and Bruna Pellini, MD, joined Lung Cancers Today at the conference to share their insights on key data.
Narjust Florez, MD, FASCO, discusses meeting highlights, the IASLC 50th Anniversary Celebration, research, and more.
Shirish M. Gadgeel, MD, discusses his presentation on the updated data, with a median follow-up of 31.1 months.
Osimertinib demonstrated a manageable safety profile for the treatment of stage III EGFR-mutated NSCLC.
Caicun Zhou, PhD, MD, presented results during the first Presidential Symposium at the IASLC 2024 WCLC.
More than one-third of patients with platinum-resistant ES-SCLC responded to treatment.
A personalized music therapy regimen also mediated postoperative dyspnea symptoms.
HR20013 was noninferior to fosaprepitant plus palonesetron at reducing nausea related to cisplatin-based chemotherapy.
Nivolumab with or without relatlimab demonstrated promising survival rates at 2 years postoperatively.
Novocure will examine TTFields at the conference, placing particular emphasis on a post-hoc analysis using data from LUNAR.
The study compared ivonescimab with pembrolizumab in locally advanced or metastatic NSCLC with PD-L1 expression.
Eric Singhi, MD, shares what he's most looking forward to at the upcoming ISALC 2024 World Conference on Lung Cancer.
Eric Singhi, MD, discusses the key milestone that will be celebrated at the conference, which will be held in San Diego.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.